---
schema_version: "secwatch.filing_event.v1"
accession: "0000929638-24-001313"
form_type: "8-K"
ticker: null
cik: "0001100397"
company_name: "Ayala Pharmaceuticals, Inc."
filed_at: "2024-03-29T23:59:59+00:00"
generated_at: "2026-06-04T05:11:18.585864+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ayala sells AL102/AL101 to Immunome for $20M cash plus 2.18M shares; up to $37.5M milestones

## Summary
- Closed sale of AL101 and AL102 programs to Immunome for $20M cash, 2,175,489 Immunome shares, and assumed liabilities.
- Up to $37.5M in additional development/commercial milestone payments from Immunome.
- March 1 Convertible Notes ($2M aggregate) converted into 6,666,666 shares of Ayala common stock upon closing.
- Immunome (Nasdaq: IMNM) will advance AL102; Ayala (OTCQX: ADXS) retains potential milestone payments.

## SEC filing metadata
- accession: 0000929638-24-001313
- form_type: 8-K
- cik: 0001100397
- company_name: Ayala Pharmaceuticals, Inc.
- filed_at: 2024-03-29T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1100397/000092963824001313/0000929638-24-001313-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1100397/000092963824001313/a8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000929638-24-001313
- JSON: https://secwatch.observer/filing/0000929638-24-001313.json
- Plain text: https://secwatch.observer/filing/0000929638-24-001313.txt

## Key facts
- M&A Transactions
  Ayala Pharmaceuticals, Inc. completed a disposition involving Immunome, Inc. for $20.0 million in cash plus 2,175,489 shares of common stock (closed 2024-03-25).
  - Action: disposition
  - Counterparty: Immunome, Inc.
  - Consideration: $20.0 million in cash plus 2,175,489 shares of common stock
  - Closing: 2024-03-25
  source text: On March 25, 2024, the Company and Purchaser consummated the Asset Sale pursuant to the Asset Purchase Agreement, such that Purchaser (i) paid an upfront purchase price of $20.0 million in cash to the Company, less certain adjustments, (ii) issued the Company 2,175,489 shares of Immunome’s common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1100397/000092963824001313/0000929638-24-001313-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.